Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
Latest in adjuvant therapy for renal cell carcinoma

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.18
Views: 921
Rating:

Dr Naomi Haas - University of Pennsylvania, Philadelphia, USA

Dr Haas speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about the latest research into adjuvant therapy for renal cell carcinoma. 

She highlights three recent trials of note;

The ASSURE trial

The ProtecT trial

The S-TRAC trial

She goes on to highlight the immune checkpoint inhibitor, PROSPER trial, looking at the use of perioperative nivolumab vs. observation in patients with localised renal cell carcinoma undergoing nephrectomy. 

Finally she discusses the recent FDA approval of sunitinib for adjuvant treatment for renal cell carcinoma. 

For more on the PROSPER trial watch the interview with Dr Lauren Harshman here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation